Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B‐Cell Malignancies

समान संसाधन

• Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects
  द्वारा: Mu, Song, और अन्य
  प्रकाशित: (2019)
• Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator
  द्वारा: Wang, Kun, और अन्य
  प्रकाशित: (2021)
• Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
  द्वारा: Tam, Constantine S., और अन्य
  प्रकाशित: (2019)
• No QTc Prolongation With Zanubrutinib: Results of Concentration‐QTc Analysis From a Thorough QT Study in Healthy Subjects
  द्वारा: Mu, Song, और अन्य
  प्रकाशित: (2020)
• Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration‐QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers
  द्वारा: Becker, Andreas, और अन्य
  प्रकाशित: (2019)